[Prevalence of antibody to adult T-cell leukemia virus in Hokkaido District] NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Prevalence of antibody to adult T-cell leukemia virus in Hokkaido District]

Hokkaido Igaku Zasshi. 1985 Nov;60(6):871-5. Unique Identifier : AIDSLINE MED/86109869
Kwon KW; Yano M; Sekiguchi S; Iwanaga M; Fujiwara S; Osato T; Higuchi M

Abstract: In order to investigate the spread of adult T-cell leukemia (ATL) virus in the inhabitants of ATL-non-endemic Hokkaido, we surveyed the antibodies to ATL-associated antigen (ATLA) in 29516 healthy individuals by indirect immunofluorescence test using MT-1 for target cell. Of the healthy inhabitants, only 219 individuals (0.74%) were anti-ATLA positive as carriers. Prevalence of anti-ATLA was 0.63% (111 of 17590) in males and 0.91% (108 of 11926) in females. This difference by sex is significant. In several regions, the inhabitants were found to show relatively high incidence (greater than 2%) of the antibodies, and these regions have a tendency to cluster around the western side of Hidaka mountains or Akan area. The highest rate (5.2%) of anti-ATLA positive carriers was shown in a certain town of Hidaka area.
Keywords: Adolescence Adult Aged Antibodies, Viral/*ANALYSIS Child Child, Preschool English Abstract Female Human HTLV-BLV Viruses/*IMMUNOLOGY Infant Japan Leukemia/*IMMUNOLOGY Male Middle Age Retroviridae Infections/EPIDEMIOLOGY/*IMMUNOLOGY JOURNAL ARTICLE

KWDadolescenceadultagedantibodies,viral/KWDanalysischildchild,preschoolenglishabstractfemalehumanhtlv-blvviruses/KWDimmunologyinfantjapanleukemia/KWDimmunologymalemiddleageretroviridaeinfections/epidemiology/KWDimmunologyjournalarticle
860530
M8650024

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .